In terms of the 1200 mg/day experimental group, the average serum testosterone levels were higher following 14 days
as compared to the levels measured at baseline (day 0). For the 800 mg/day Resettin®/www.selleckchem.com/screening/pi3k-signaling-inhibitor-library.html MyTosterone™ treatment selleck inhibitor group, the level of serum testosterone did not differ significantly between baseline and following 14 consecutive days of treatment (ANOVA-RM; p > 0.05). Serum testosterone levels for both groups are illustrated graphically in Figure 1. Furthermore, the results indicated that the serum testosterone levels of participants who were administered 1200 mg/day of Resettin®/MyTosterone™ were 38.04% higher than the serum testosterone levels of participants in the placebo control group Figure 1. However, there were no statistically significant differences in the average
serum https://www.selleckchem.com/products/Belinostat.html testosterone levels of either the 800 mg/day or 1200 mg/day Resettin®/MyTosterone™ treatment groups when compared to participants within the respective placebo control groups (ANOVA-RM; p > 0.05). Figure 1 Baseline subtracted serum testosterone levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the total serum testosterone levels from participants after 3, 7 and 14 days of 800 mg/day placebo (a) or Resettin®/MyTosterone™, or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental Vildagliptin group had between 9 and 10 participants, and results are indicative of one trial. Error bars denote standard deviation of the experimental mean. Given that aromatase is capable of converting testosterone into E2, the serum concentrations of E2 were also evaluated by ELISA in all participants. Serum E2 levels did not significantly change relative to baseline levels. Further, there were no significant differences in the average serum E2 levels of the participants in the 800 mg/day and 1200 mg/day Resettin®/MyTosterone™ treatment groups as compared to the placebo control groups (Figure 2;
ANOVA-RM; p > 0.05). Interestingly, when all serum E2 concentrations were adjusted by subtracting their baseline concentrations, results revealed a statistically significant reduction in the average serum E2 concentration of the 1200 mg/day Resettin®/MyTosterone™ treatment group compared to that of the 1200 mg/day placebo control group (Figure 2; ANOVA-2; p < 0.05). Figure 2 Baseline subtracted serum E2 levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the serum E2 levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Resettin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are indicative of one trial.